How did AQST's Q1 2025 EPS forecast compare to past trends?

Aquestive Therapeutics' (AQST) Q1 2025 EPS forecast is not currently available. However, using the most recent data from Q4 2024, the EPS was -$0.19, which is a decrease from the Q4 2023 EPS of -$0.41. This suggests a trend of improving EPS over the past year.

1. **Comparison with Q4 2024 EPS**: The EPS of -$0.19 for Q1 2025 forecast is better than the -$0.41 recorded in Q4 2023, indicating an improvement in the company's financial performance over the period.
2. **Trend Analysis**: The EPS has shown a significant increase from -$1.83 in Q1 2021 to -$0.41 in Q4 2023, which suggests a positive trend in the company's financial health. However, the recent EPS of -$0.19 in Q4 2024 indicates a slight setback.

The company's EPS is expected to decrease in 2025 compared to 2024, reflecting the challenges and expenses the company is facing, such as increased net losses and decreased revenues. Despite these challenges, the company's focus on strategic developments and potential product approvals offers optimism for future financial performance.